BALTIMORE — Despite recurring pharma quality problems, drugmakers are still inclined to meet minimum manufacturing standards set by regulators, rather than make quality central to their business model.
Drug Quality Still Lacking; FDA Considering QbD Incentives
- Post author:Sam
- Post published:April 7, 2016
- Post category:Washington Drug Letter